Psoriatic Arthritis

Psoriatic Arthritis

Psoriatic Arthritis

The Changing Landscape of Axial Spondyloarthritis: Current and Emerging Agents for Individualized Treatment

Calendar
Register
When:
February 11, 2020 @ 6:00 pm – 7:30 pm
2020-02-11T18:00:00-05:00
2020-02-11T19:30:00-05:00
Where:
Miami
FL
Summit Meetings

Tuesday, February 11, 2020

5:30 – 6:00 PM: Registration/Dinner
6:00 – 7:30 PM: Scientific Session

Venue TBD
Miami, FL

FEATURES

– Virtual Reality headsets provided to all attendees for viewing this presentation only
– Interactive, case-based learning environment
– Create your own personalized poster
– iPads provided to enhance learning experience and enable real-time Q&A

FACULTY

Abhijeet Danve MD FACP RhMSUS
Assistant Professor of Clinical Medicine
Director of Spondyloarthritis Program
Yale School of Medicine

Elaine Tozman, MD
Associate Professor
University of Miami Miller School of Medicine
Miami, FL

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Examine the specific domains of AxSpA and their relationship to quality of life
  • Review current and emerging therapies used for AxSpA
  • Evaluate the IL-17/23 axis and its relationship to the pathophysiology of AxSpA
  • Compare outcomes measures used in clinical trials versus those that may be more practical for use in clinical practice

TARGET AUDIENCE

This activity is intended for rheumatologists and other healthcare professionals involved in the management of patients with axial spondyloarthritis.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity is planned and produced in accordance with ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with axial spondyloarthritis..

CNE Credits:1.5 ANCC Contact Hour(s)

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at [email protected]

This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/ Complete Conference Management (CCM). 
This activity is supported by an educational grant from Lilly.

mlg-logos-2022
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
Home
Clinical Toolkit
PsA and COVID-19
Diagnosis
Treatment Considerations
Resources
Patient Toolkit
What Are PsA and COVID-19
Living With PsA
FAQ
Resources
Can We Talk?
CME Activities
Poster Portal
Animations
About Us
Contact

Updates in the Treatment and Prevention of COVID-19

EUA of Bamlanivimab Plus Etesevimab Expanded to Include Younger Pediatric Patients

The emergency use authorization (EUA) for bamlanivimab plus etesevimab now includes an indication for treatment and post-exposure prophylaxis for children and newborn babies who are at high risk for severe disease. The expansion of the EUA is supported by a trial of 125 pediatric patients with at least one risk factor for severe illness; the study had safety and efficacy data similar to findings for adolescents and adults.

For more information visit www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19

 

Oral Antiviral Therapies With Emergency Use Authorization (EUA) for COVID-19

Two new oral antiviral therapies received emergency use authorization (EUA) for COVID-19: Paxlovid™ (nirmatrelvir tablets and ritonavir tablets, co-packaged) and molnupiravir. Both therapies are authorized for the treatment of mild-to-moderate COVID-19 in certain people who are at high risk of progressing to severe illness.

In the EPIC-HR clinical trial, nirmatrelvir/ritonavir significantly reduced the risk of hospitalization or death from any cause by 88% compared with placebo. This treatment is indicated for adults and pediatric patients, 12 years of age and older who weigh at least 40 kilograms. Side effects include an impaired sense of taste, diarrhea, high blood pressure, and muscle aches. The safety and effectiveness of this combination therapy continue to be evaluated.

The main outcome measure of the MOVe-OUT trial of molnupiravir was the percentage of people who were hospitalized or died due to any cause during 29 days of follow-up. Compared with 9.7% of people who received placebo, 6.8% of those in the molnupiravir group were hospitalized or died. One person who received molnupiravir died versus nine people in the placebo group. Molnupiravir is not recommended for pregnant women or for those people younger than 18 years of age because of its effect on bone and cartilage growth.

For more information regarding the EUA for these oral antivirals, visit the following FDA URLs:

www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19

www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain

 

FDA Authorized Emergency Use Authorization (EUA) for Long-Acting Monoclonal Antibodies as Pre-Exposure Prophylaxis of COVID-19

Evusheld™ (tixagevimab co-packaged with cilgavimab and administered together) has been granted EUA for the prevention of COVID-19 in certain people with compromised immune systems or with a history of severe adverse reactions to a COVID-19 vaccine or any of its components. This combination is not meant to be a substitute for vaccination for those who have no contraindications to a COVID-19 vaccine.

The PROVENT clinical trial demonstrated a 77% reduction in the risk of developing COVID-19 compared with placebo, and protection appears to have been maintained through six months. Safety and efficacy of the tixagevimab/cilgavimab combination continues to be investigated.

For more information, visit www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure